Rhopressa®
Netarsudil is a rho kinase (ROCK) inhibitor and norepinephrine transporter (NET) inhibitor for glaucoma. Novel mechanism of action targeting trabecular outflow.
| Dosage Form | Ophthalmic Solution |
| Strength | 0.02% |
| Storage | Store at 2–8°C. |
| Category | Ophthalmics |
| Availability | Available for Transfer |
Open-angle glaucoma; ocular hypertension.
Dual mechanism: inhibits rho kinase (ROCK), relaxing trabecular meshwork and increasing conventional outflow; inhibits NET, reducing aqueous humor production via decreased episcleral venous pressure.
Each Burrard Pharmaceuticals technology transfer package for Netarsudil includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.